Heike Woehling
Holzkirchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 13, 2017
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 20, 2017
Longitudinal assessment of the impact of multiple switches between a biosimilar and its reference product on efficacy parameters.
Journal: Pharmaceutical statistics
Published: May 24, 2017
The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
Journal: The British journal of dermatology
Published: October 25, 2016
GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
Journal: British journal of clinical pharmacology
Published: July 29, 2016
Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
Journal: Advances in therapy
Published: December 14, 2015
Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
Journal: Biologics in therapy
Published: November 20, 2014
Assessing switchability for biosimilar products: modelling approaches applied to children's growth.
Journal: Pharmaceutical statistics
Published: May 16, 2014
Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
Journal: Biologics in therapy
Published: May 15, 2014
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.
Journal: Biologics in therapy
Published: April 02, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026